EDIT vs NOC · rev $32.3M vs P/E 17, rev $41.95B
Editas Medicine Inc (EDIT) versus Northrop Grumman Corporation (NOC) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Northrop Grumman Corporation (NOC) is a aerospace & defense company listed on NYSE.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported NOC revenue for 2025-12-31 was $41.95B. Net income was $4.18B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
EDIT currently screens at market cap $375.2M. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
Not investment advice. Open the EDIT and NOC stock pages for the full models.
Not investment advice.